Cancer Genetics, Inc. (CGIX) EPS Estimated At $-0.11

March 21, 2018 - By Vivian Park

 Cancer Genetics, Inc. (CGIX) EPS Estimated At $ 0.11
Investors sentiment decreased to 0.57 in 2017 Q3. Its down 0.60, from 1.17 in 2017Q2. It dived, as 5 investors sold Cancer Genetics, Inc. shares while 9 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.58 million shares or 6.28% less from 2.76 million shares in 2017Q2 were reported.
18,600 were reported by Virtu Fin Limited Liability Corporation. Two Sigma Ltd Liability Co owns 14,616 shares or 0% of their US portfolio. Thompson Davis Co owns 46,975 shares or 0.22% of their US portfolio. Moreover, Fincl Bank Of America De has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Granahan Invest Ma invested 0.05% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Limited Company, a United Kingdom-based fund reported 454 shares. Next Group Incorporated invested in 2,500 shares. Royal National Bank Of Canada holds 0% or 809 shares in its portfolio. 24,212 are held by Savings Bank Of Montreal Can. Pnc Fincl Svcs Gp has invested 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Tower Rech Limited Liability Company (Trc) invested in 1,342 shares. Hrt Fincl Limited Liability Corp accumulated 0.05% or 15,301 shares. Wells Fargo Mn accumulated 0% or 15,823 shares. Morgan Stanley stated it has 17,998 shares. Vanguard Grp Inc Inc stated it has 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX).

Since December 15, 2017, it had 1 insider buy, and 0 selling transactions for $24,339 activity.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.11 EPS on March, 22.They anticipate $0.04 EPS change or 26.67 % from last quarter’s $-0.15 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -31.25 % EPS growth. The stock decreased 2.63% or $0.05 during the last trading session, reaching $1.85. About 83,828 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since March 21, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Cancer Genetics has $8 highest and $6.0 lowest target. $6.40’s average target is 245.95% above currents $1.85 stock price. Cancer Genetics had 11 analyst reports since March 11, 2016 according to SRatingsIntel. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Thursday, December 7 by Maxim Group. The rating was maintained by H.C. Wainwright on Wednesday, November 29 with “Buy”. The company was maintained on Tuesday, February 6 by H.C. Wainwright. The firm has “Neutral” rating by Janney Capital given on Friday, March 11. The firm has “Buy” rating by Rodman & Renshaw given on Monday, September 26. The firm earned “Buy” rating on Thursday, September 21 by H.C. Wainwright. As per Tuesday, January 16, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $600 target in Tuesday, August 15 report. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Tuesday, March 15 by Aegis Capital.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $44.87 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: